Maribavir: a promising new antiherpes therapeutic agent
KK Biron - New Concepts of Antiviral Therapy, 2006 - Springer
Maribavir (1263W94) is a potent and selective, orally bioavailable antiviral drug with a novel
mechanism of action against CMV This benzimidazole riboside (1-(ß-L-ribofuranosyl)-2 …
mechanism of action against CMV This benzimidazole riboside (1-(ß-L-ribofuranosyl)-2 …
Cytomegalovirus in hematopoietic stem cell transplant recipients: prevention, diagnosis, and treatment
JF Camargo - Emerging transplant infections: clinical challenges and …, 2021 - Springer
Human herpesvirus 5, better known as cytomegalovirus (CMV), infects 50–90% of the adult
population worldwide and is the most common opportunistic infection in allogeneic …
population worldwide and is the most common opportunistic infection in allogeneic …
The Synthesis and Anti-Cytomegalovirus Activity of Piperidine-4-Carboxamides
Treatment options for human cytomegalovirus (CMV) remain limited and are associated with
significant adverse effects and the selection of resistant CMV strains in transplant recipients …
significant adverse effects and the selection of resistant CMV strains in transplant recipients …
Prophylactic and pre-emptive therapy for cytomegalovirus infection in kidney transplant patients using oral valganciclovir
L Guirado, JM Díaz, C Facundo… - Nefrología (English …, 2008 - revistanefrologia.com
Antecedentes: La enfermedad por citomegalovirus (CMV) es un problema sanitario muy
importante en receptores de trasplante de órgano sólido (TOS). Una dosis diaria de …
importante en receptores de trasplante de órgano sólido (TOS). Una dosis diaria de …
Cytomegalovirus
A Safdar, D Armstrong - Principles and practice of transplant infectious …, 2019 - Springer
In the general population, cytomegalovirus (CMV) is a common infection that is frequently
acquired at a young age; one in three children in the United States are infected with CMV. In …
acquired at a young age; one in three children in the United States are infected with CMV. In …
Management of late, recurrent, and resistant cytomegalovirus in transplant patients
RK Avery - Transplantation Reviews, 2007 - Elsevier
The timing and incidence of post-transplant cytomegalovirus (CMV) infections have changed
in the era of prophylaxis and preemptive therapy. Late, recurrent, and ganciclovir-resistant …
in the era of prophylaxis and preemptive therapy. Late, recurrent, and ganciclovir-resistant …
Leflunomide: a small step forward in meeting the urgent need for treatment of drug-resistant cytomegalovirus infection
DR Snydman - Transplantation, 2010 - journals.lww.com
There is an urgent, and as yet unmet, need for therapy for cytomegalovirus (CMV) infection
resistant to ganciclovir in solid organ and bone marrow transplantation. Since the …
resistant to ganciclovir in solid organ and bone marrow transplantation. Since the …
Characterization of the DNA-and dNTP-binding activities of the human cytomegalovirus DNA polymerase catalytic subunit UL54
F Picard-Jean, I Bougie, M Bisaillon - Biochemical Journal, 2007 - portlandpress.com
The catalytic subunit of the human cytomegalovirus DNA polymerase is critical for the
replication of the virus. In the present study, we report the expression and purification of a …
replication of the virus. In the present study, we report the expression and purification of a …
Tratamiento profiláctico y anticipado de la infección por citomegalovirus en pacientes trasplantados renales mediante vanglanciclovir oral
L Guirado, JM Díaz, C Facundo, A Maderuelo… - …, 2008 - revistanefrologia.com
Antecedentes: La enfermedad por citomegalovirus (CMV) es un problema sanitario muy
importante en receptores de trasplante de órgano sólido (TOS). Una dosis diaria de …
importante en receptores de trasplante de órgano sólido (TOS). Una dosis diaria de …
UL 54 foscarnet mutation in an hematopoietic stem cell transplant recipient with cytomegalovirus disease
K Gregg, M Hakki, DR Kaul - Transplant Infectious Disease, 2014 - Wiley Online Library
We present a case of foscarnet (FOS) resistance arising from a UL 54 mutation after a short
duration of FOS exposure, which has not been previously described in a stem cell transplant …
duration of FOS exposure, which has not been previously described in a stem cell transplant …